resulting incremental cost per QALY of Յ7721 demonstrated that maintenance therapy with rituximab when compared to observation was cost-effective. The cost per QALY was very robust when subject to extensive one-way and probabilistic sensitivity analysis. Probabilistic sensitivity analyses indicated that the likelihood of the ICER being below Յ10,000 was 90%. CONCLUSION: From the perspective of UK NHS, maintenance rituximab when compared to observation alone for the treatment of relapsed/refractory follicular NHL patients responding to induction therapy is a highly cost-effective treatment.
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COST-UTILITY ANALYSIS OF OXALIPLATIN IN THE ADJUVANT TREATMENT OF COLON CANCER IN HUNGARY
Muszbek N 1 , Odhiambo R 2 1 UnitedBiosource Corporation, London, UK, 2 sanofi-aventis Zrt, Budapest, Hungary OBJECTIVES: In Hungary the standard therapy in the adjuvant treatment of stage III colon cancer is the DeGramont-protocol, a combination of 5-fluorouracil and leucovorin. In the MOSAIC trial the addition of oxaliplatin (FOLFOX4) improved the efficacy of the standard therapy in this patient group. The aim of our study was to evaluate the cost-effectiveness of FOLFOX4 compared to standard therapy in Hungary. METHODS: The cost-utility analysis of the FOLFOX4 therapy was based on the MOSAIC trial. The efficacy data of the MOSAIC trial was extrapolated for lifetime, while utilities values were incorporated from published sources. Age and gender specific general mortality rates and utilities were derived from epidemiology data of the Hungarian population and published utilities based on the EQ-5D questionnaire. The analysis was accomplished from payer perspective. Thus, only direct medical costs were taken into account. Resource use was based on Hungarian treatment patterns and unit costs. Costs and outcomes were discounted at 5%. Cost-effectiveness was measured in terms of incremental cost per quality-adjusted life year saved (QALY), incremental cost per disease-free years (DFY) and incremental cost per life-years saved (LYS). One-way sensitivity analysis was employed. RESULTS: Compared to DeGramont therapy, FOLFOX4 resulted in an additional 0.455 QALY, 0.531 LYS, 0.958 DFY and HUF 1, 310, 064 (5, 240€) per patient. The cost for one QALY was HUF 2,880,342 (11,521€), while for one DFS and LYS was HUF 1, 367, 712 (5, 471€) and HUF 2, 468, 660 (9, 875€) , respectively. The results were most sensitive to discount rate, general population data and the cost of chemotherapy. CONCLU-SION: Based on the possible thresholds in Hungary, and the €20,000/QALY quoted in countries of the EU zone, FOLFOX4 is a cost-effective strategy in Hungary for the postoperative adjuvant treatment of patients with stage III colon cancer compared to the DeGramont protocol. The aim of the study was to analyze the costeffectiveness of sunitinib malate, a novel cancer treatment, as a second-line therapy for metastatic renal cell carcinoma (mRCC) after first-line cytokine treatment compared with current Finnish treatment practice. Cytokine therapy is currently the standard first line treatment for mRCC. Until recently, treatments with proven efficacy after the failure of first line cytokine therapy have not been available. METHODS: Information for analyses was gathered from clinical trials, the literature and patient records from two Finnish university hospitals. Clinical experts treating mRCC-patients in Finland provided the information on current practices for the sunitinib treatment. A comprehensive probabilistic decision-analytic model was developed using WinBUGS software to estimate the cost-effectiveness and expected value of perfect information (EVPI) of sunitinib malate. An EVPI approach was used to estimate the expected costs of decision uncertainty. A societal perspective was assumed in all analyses to avoid suboptimal decisions. RESULTS: The Kaplan-Meier survival estimates after cytokine failure for local patients (n = 39) were 3.8 months (95% CI, 2.16-5.51) and 1.4 months (95% CI, 0.7-2.17) for overall and progression-free survival, respectively. When compared to the current Finnish treatment practice, sunitinib prolonged life expectancy by 1 year and resulted in a progression-free time of 6.3 months and in 0.7 QALYs gained. Over a five-year time period, an incremental cost-effectiveness ratio (ICER) of 42,877€ per QALY was obtained. Sunitinib was estimated to have an 88% probability of being cost-effective at the willingness-to-pay level of 45,000€/QALY. The population EVPI for the decision between sunitinib-treatment and current Finnish treatment practice was 607,000€ at a willingness-to-pay level of 42,500€. CONCLUSION: Sunitinib malate results in improved survival and is potentially cost-effective as a secondline treatment of mRCC compared to the current clinical practice used in Finnish hospitals. Roche Brazil, Sao Paulo, SP, Brazil OBJECTIVES: Maintenance therapy with rituximab has shown significant improvements in overall survival and progression-free survival (PFS) when compared with observation in patients with relapsed/refractory follicular lymphoma (van Oers et al., 2006) . The primary objective of this analysis was to estimate the incremental cost-efectiveness ratio (ICER) of rituximab maintenance therapy versus observation alone, based on data from the EORTC 20981 study. METHODS: Rituximab maintenance therapy (375 mg/m2 every 3 months) was evaluated using a Markov model. All patients entered in the model following response to CHOP chemotherapy +/-rituximab as induction therapy. PFS and Overall Survival (OS) following rituximab maintenance were extrapolated from 2-year Kaplan-Meier curves from the study data using a parametric approach. CoxSnell and deviance residuals were analysed. Quality-of-life utility values were derived from a study of 165 patients using the EQ-5D questionnaire. Direct annual medical costs including adverse events, drug acquisition, administration and preparation were estimated accordingly to a Delphi panel with Brazilian haematologists. Costs were reported in 2007 Brazilian Reais. Both costs and outcomes were discounted at 3.5% rate according to NICE/UK recommendation. In order to assess uncertainty, probabilistic sensitivity analyses were also performed. A lifetime horizon and a payer perspective in Brazil were adopted. RESULTS: Rituximab maintenance resulted in a gain of 1.79 QALYs (5.96 vs. 4.17) at an incremental cost of R$57,595 The ICER of rituximab maintenance vs. observation alone is, therefore, estimated to be R$32,236 per QALY gained. The ICER of rituximab maintenance was sensitive to the duration of treatment benefit, discount rate and drug cost. CONCLUSION: In patients responding to induction therapy, rituximab maintenance therapy improves overall survival and progression-free survival compared with observation alone. Results suggest that maintenance therapy with rituximab is a cost-effective intervention for the management of patients with follicular lymphoma in the Brazilian Private Healthcare System.
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PCN50 COST SHIFTING EFFECT IN DRG BASED ANTI-CANCER THERAPIES IN HUNGARY
Jozsa G University of West Hungary, Sopron, Hungary OBJECTIVES: The goal of research was to investigate the cost of DRG based anti-cancer chemotherapies. Costs for investigated chemotherapies have been allocated to oncology centers from the budget of National Heath Fund Administration, based on DRG-reimbursement. METHODS: Cost analysis of chemotherapy protocols has been conducted, from the perspective of National Heath Fund Administration, focusing on cost of medication, hospitalisation and the total expenditure of protocols.
RESULTS:
The standard process of protocol-expenditure calculation has been identified. The drug related cost has been based on the ex-factory prices of medicines. Expenditures of hospitalisation have been calculated on the days of total length of drug administration and not on term of hospitalisation. Chemotherapies, containing per os anti-cancer medication have been found over-charged. The cost ratio of oral drug and protocol expenses has been found lower than the average of oncology protocols, from 1,75 to 26.9%. Consequetly, the cost of hospitalisaton has been over-represented in these protocolls, although these treatments have reqired less hospitalisation. Using per os chemotherapy protocols has resulted idle capacity in utilization of protocol-expenditures. CONCLUSION: The cost of hospitalisation based on "days of treatment" hasn't reflected correctly the occurrent expenses. Per os chemotherapies alone should have been reimbursed as outpatient care and not involved into DRG based hospital care. The cost of protocols, containing per os and i.v. compounds in combination should have been calculated on a real-cost basis, considering the days of hospitalisation. We first attempted to calculate the burden of cancer for South Africa using Statistics SA, South African death registry and the National Cancer Registry data. Using different data sets we then differentiated the data in order to estimate the public and private sector burden of cancer. By using the latest South African National Health Accounts and medical insurance data, we then calculated the direct monetary health care resources for cancer and other diseases. Lastly we attempted to calculate the indirect costs associated with cancer and other diseases using the human capital methodology. We were able to compare burden of cancer, cardiovascular disease, diabetes, HIV/AIDS, injuries, mental disease, respiratory disease and all other diseases to the direct monetary health care resources as well as the indirect costs associated with disease. RESULTS: HIV/AIDS and injuries contributed 30.9% and 14.3% to the burden of disease in South Africa while cancer was 3.1%. When comparing the direct health care cost as a percentage of total health care spending to the cancer DALY as a percentage of total DALY, the ratio was 1.07. This indicates that, from a direct health care cost perspective, direct health care cost consumption was proportionate to the burden. However, when comparing direct health care cost percentage to indirect costs percentage, the ratio for cancer is 0.36. Similar results were seen in the public and private sector. CON-CLUSION: From a societal perspective, it appears that too little resources are allocated to cancer and some other chronic diseases in South Africa.
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